Hereditary Cancer in Clinical Practice (Oct 2019)
Survival by colon cancer stage and screening interval in Lynch syndrome: a prospective Lynch syndrome database report
- Mev Dominguez-Valentin,
- Toni T. Seppälä,
- Julian R. Sampson,
- Finlay Macrae,
- Ingrid Winship,
- D. Gareth Evans,
- Rodney J. Scott,
- John Burn,
- Gabriela Möslein,
- Inge Bernstein,
- Kirsi Pylvänäinen,
- Laura Renkonen-Sinisalo,
- Anna Lepistö,
- Annika Lindblom,
- John-Paul Plazzer,
- Douglas Tjandra,
- Huw Thomas,
- Kate Green,
- Fiona Lalloo,
- Emma J. Crosbie,
- James Hill,
- Gabriel Capella,
- Marta Pineda,
- Matilde Navarro,
- Joan Brunet Vidal,
- Karina Rønlund,
- Randi Thyregaard Nielsen,
- Mette Yilmaz,
- Louise Laurberg Elvang,
- Lior Katz,
- Maartje Nielsen,
- Sanne W. ten Broeke,
- Sigve Nakken,
- Eivind Hovig,
- Lone Sunde,
- Matthias Kloor,
- Magnus v Knebel Doeberitz,
- Aysel Ahadova,
- Noralane Lindor,
- Verena Steinke-Lange,
- Elke Holinski-Feder,
- Jukka-Pekka Mecklin,
- Pål Møller
Affiliations
- Mev Dominguez-Valentin
- Department of Tumor Biology, Institute of Cancer Research, Oslo University Hospital
- Toni T. Seppälä
- Department of Gastrointestinal Surgery, Helsinki University Central Hospital
- Julian R. Sampson
- Division of Cancer and Genetics, Institute of Medical Genetics, Cardiff University School of Medicine
- Finlay Macrae
- The Royal Melbourne Hospital
- Ingrid Winship
- The Royal Melbourne Hospital
- D. Gareth Evans
- University of Manchester & Manchester University Hospitals Foundation Trust
- Rodney J. Scott
- University of Newcastle and the Hunter Medical Research Institute
- John Burn
- University of Newcastle
- Gabriela Möslein
- University Witten-Herdecke
- Inge Bernstein
- Department of Surgical Gastroenterology, Aalborg University Hospital
- Kirsi Pylvänäinen
- Central Finland Central Hospital, Education and Research
- Laura Renkonen-Sinisalo
- Department of Gastrointestinal Surgery, Helsinki University Central Hospital
- Anna Lepistö
- Department of Gastrointestinal Surgery, Helsinki University Central Hospital
- Annika Lindblom
- Karolinska Institutet
- John-Paul Plazzer
- The Royal Melbourne Hospital
- Douglas Tjandra
- University of Melbourne
- Huw Thomas
- St Mark’s Hospital, Department of Surgery and Cancer, Imperial College London
- Kate Green
- University of Manchester & Manchester University Hospitals Foundation Trust
- Fiona Lalloo
- University of Manchester & Manchester University Hospitals Foundation Trust
- Emma J. Crosbie
- University of Manchester and St Mary’s Hospital
- James Hill
- University of Manchester & Manchester University Hospitals Foundation Trust
- Gabriel Capella
- Hereditary Cancer Program, Catalan Institute of Oncology, Insititut d’Investigació Biomèdica de Bellvitge (IDIBELL), ONCOBELL Program
- Marta Pineda
- Hereditary Cancer Program, Catalan Institute of Oncology, Insititut d’Investigació Biomèdica de Bellvitge (IDIBELL), ONCOBELL Program
- Matilde Navarro
- Hereditary Cancer Program, Catalan Institute of Oncology, Insititut d’Investigació Biomèdica de Bellvitge (IDIBELL), ONCOBELL Program
- Joan Brunet Vidal
- Hereditary Cancer Program, Catalan Institute of Oncology, Insititut d’Investigació Biomèdica de Bellvitge (IDIBELL), ONCOBELL Program
- Karina Rønlund
- Department of Clinical Genetics, Vejle Hospital
- Randi Thyregaard Nielsen
- Department of Surgery, Regional Hospital West Jutland
- Mette Yilmaz
- Department of Oncology, Aalborg University Hospital
- Louise Laurberg Elvang
- Department of Pathology, Herlev Gentofte University Hospital
- Lior Katz
- High Risk and GI Cancer prevention Clinic, Gatro-Oncology Unit, The Department of Gastroenterology, Sheba Medical Center
- Maartje Nielsen
- Leids Universitair Medisch Centrum
- Sanne W. ten Broeke
- Leids Universitair Medisch Centrum
- Sigve Nakken
- Department of Tumor Biology, Institute of Cancer Research, Oslo University Hospital
- Eivind Hovig
- Department of Tumor Biology, Institute of Cancer Research, Oslo University Hospital
- Lone Sunde
- Department of Clinical Genetics, Aarhus University Hospital
- Matthias Kloor
- Department of Applied Tumor Biology, Institute of Pathology, University Hospital Heidelberg
- Magnus v Knebel Doeberitz
- Department of Applied Tumor Biology, Institute of Pathology, University Hospital Heidelberg
- Aysel Ahadova
- Department of Applied Tumor Biology, Institute of Pathology, University Hospital Heidelberg
- Noralane Lindor
- Department of Health Sciences Research, Mayo Clinic
- Verena Steinke-Lange
- Medizinische Klinik und Poliklinik IV, Campus Innenstadt, Klinikum der Universität München
- Elke Holinski-Feder
- Medizinische Klinik und Poliklinik IV, Campus Innenstadt, Klinikum der Universität München
- Jukka-Pekka Mecklin
- Department of Surgery, Central Finland Central Hospital
- Pål Møller
- Department of Tumor Biology, Institute of Cancer Research, Oslo University Hospital
- DOI
- https://doi.org/10.1186/s13053-019-0127-3
- Journal volume & issue
-
Vol. 17,
no. 1
pp. 1 – 6
Abstract
Abstract Background We previously reported that in pathogenic mismatch repair (path_MMR) variant carriers, the incidence of colorectal cancer (CRC) was not reduced when colonoscopy was undertaken more frequently than once every 3 years, and that CRC stage and interval since last colonoscopy were not correlated. Methods The Prospective Lynch Syndrome Database (PLSD) that records outcomes of surveillance was examined to determine survival after colon cancer in relation to the time since previous colonoscopy and pathological stage. Only path_MMR variants scored by the InSiGHT variant database as class 4 or 5 (clinically actionable) were included in the analysis. Results Ninety-nine path_MMR carriers had no cancer prior to or at first colonoscopy, but subsequently developed colon cancer. Among these, 96 were 65 years of age or younger at diagnosis, and included 77 path_MLH1, 17 path_MSH2, and 2 path_MSH6 carriers. The number of cancers detected within 3.5 years after previous colonoscopy were 9, 43, 31 and 13, respectively. Of these, 2, 8, 4 and 3 were stage III, respectively, and only one stage IV (interval 2.5–3.5 years) disease. Ten-year crude survival after colon cancer were 93, 94 and 82% for stage I, II and III disease, respectively (p 3.5 years before diagnosis, was 89, 90, 90 and 92%, respectively (p = 0.91). Conclusions In path_MLH1 and path_MSH2 carriers, more advanced colon cancer stage was associated with poorer survival, whereas time since previous colonoscopy was not. Although the numbers are limited, together with our previously reported findings, these results may be in conflict with the view that follow-up of path_MMR variant carriers with colonoscopy intervals of less than 3 years provides significant benefit.
Keywords